TSXV: VIMYInvestor Centre
Vimy Pharma
Contact us

Investor Centre

Reliable Canadian supply for a healthier tomorrow.

Listed
TSXV: VIMY
Manufacturing
Canada

Strategy & Business

Vimy Pharma develops and manufactures generic semaglutide in Canada, supplied in vials, for the Canadian market and international partners.

Why Vimy Pharma

Canada is the first G7 country to allow generic semaglutide sales, and the world’s second-largest semaglutide market. Vimy Pharma is positioned to become a leading domestic source of supply for this growing market.

  • A clear window. The U.S. and EU are expected to remain patent-protected until 2031 and beyond.
  • De-risked development. Two Health Canada submissions filed.
  • Domestic advantage. Health Canada has proposed prioritizing generic submissions involving domestic manufacturing.
  • Experienced team. Leaders who have taken semaglutide through Health Canada before.

Key Facts

1st

G7 jurisdiction to allow generic semaglutide sales.1

$4.1B

Canadian semaglutide market.2

Foreign dependence

Canada currently relies on foreign manufacturers for semaglutide.

2

Generic submissions filed with Health Canada in 2026.

$22.5M

Raised to date. Fully funded through development and approval.

K2

K2 & Associates, a $1B Toronto-based hedge fund, is our anchor investor.

Corporate Presentation

Vimy Pharma corporate presentation, November 2026

Our strategy, milestones, market and team in one document.

Download PDF

1. Reddie & Grose LLP, Changes in the Ozempic Patent Landscape, February 9, 2026.
2. Apotex Health Corp., FQ2/27 Preview: Last tough comp before H2, inflection; gOzempic opportunity revised higher, Doug Miehm, 6 October 2026 (attributed to SDM/Loblaws); UBS Global Research, Eli Lilly and Co., Michael Yee et al., 16 July 2026 Statistics Canada CHMS (2022-2024); 68% of Canadian adults are overweight or living with obesity.The Globe and Mail, January 30, 2026.

Financials & Filings

Vimy Pharma’s financial statements, MD&A and other regulatory filings are available on SEDAR+, Canada’s official filing system.

View filings on SEDAR+

Corporate Governance

Board of directors

Dave Suchon

CEO, Co-Founder & Director

Farris Smith

President, Co-Founder & Director

Chris Burkett

COO, GC, Co-Founder & Director

Riccardo Trecroce

Director

Darryl Firsten

Director

Zachary Goldenberg

Director

Full biographies: About.

Committees

CommitteeMembers
Audit CommitteeFarris Smith, Darryl Firsten, Zachary Goldenberg
Compensation CommitteeChris Burkett, Darryl Firsten, Riccardo Trecroce
Nominating and Corporate Governance CommitteeChris Burkett, Darryl Firsten, Riccardo Trecroce

Governance documents

Governance documents, including committee charters and corporate policies, are filed on SEDAR+.

View documents on SEDAR+

Auditor and transfer agent

AuditorBaker Tilly HMA LLP
Transfer agentOdyssey Trust Company

Capital structure

Common shares outstanding32,347,829
Agents’ warrants249,194
Stock options457,306
Fully diluted33,054,329

After giving effect to the Qualifying Transaction, including stock options granted on closing.

Corporate structure

Vimy Pharmaceuticals Corp.Incorporated in British Columbia · TSX Venture Exchange: VIMY

Investor relations contact

Phone
416-554-8412
Head office
Vimy Pharmaceuticals Corp.
2 Bloor Street West, Suite 2002
Toronto, ON M4W 3E2

Email alerts

Get news releases, financial results and event notices by email.

Thanks for subscribing. We’ll send Vimy Pharma news to your inbox.
Sorry, something went wrong. Please try again, or email us at ir@vimypharma.com.

Cautionary note regarding forward-looking statements. Statements on this website, including the information set forth as to the future financial or operating performance of the Company, that are not current or historical factual statements may constitute “forward-looking” information within the meaning of applicable securities laws. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. When used on this website, such statements may include, among other language, such words as “may”, “will”, “expect”, “believe”, “plan”, “anticipate”, “intend”, “estimate” and other similar terminology. These statements reflect current expectations, estimates and projections regarding future events and operating performance and speak only as of the date they are made. Readers should not place undue reliance on forward-looking statements and should not rely upon this information as of any other date. These forward-looking statements involve a number of risks and uncertainties including, but not limited to:

  • failure to obtain approval from Health Canada for the Company’s semaglutide products and production sites, on the anticipated timeline or at all;
  • failure to obtain timely receipt of any other required regulatory approvals;
  • ongoing oversight and review of the Company’s products and facilities by regulatory and governmental agencies, including Health Canada and, if applicable, equivalent agencies outside of Canada, which can potentially delay facility inspections and product approvals critical to the Company’s supply continuity and new product launches and/or result in import and export restrictions and the halting of production at the facilities of manufacturing partners;
  • ability of the Company’s manufacturing partners to perform to the required specifications of the Company’s products resulting in delays or issues with the Company’s submissions or products;
  • ability to obtain components, raw materials or products supplied by third parties and other manufacturing and related supply difficulties, interruptions and delays;
  • failure to raise sufficient funding to meet development plans and budgets, satisfy contractual obligations and additional capital needs generally;
  • ability to maintain and enforce the protection afforded by any intellectual property or regulatory exclusivity rights;
  • the impact of changing conditions and increasing competition in the pharmaceutical and branded consumer health and wellness markets;
  • ability to compete against companies that are larger and have greater financial, technical and human resources than the Company, as well as other competitive factors, such as technological advances achieved, patents obtained and new products introduced by competitors;
  • reliance on third party contract manufacturers to manufacture the Company’s products on favourable terms;
  • risk of patent applications and/or granting of patents of similar products being filed by a competitor;
  • the Company’s lack of operating history;
  • ability to bring products to market first, or to do so in a timely and cost-efficient manner or in a manner sufficient to grow the Company’s business, replace lost revenue resulting from industry-wide price erosion or take advantage of new technological efficiencies, including artificial intelligence and quantum computing;
  • changes in prescription recommendations or behaviours by clinical commissioning groups or other healthcare groups in Canada or any future jurisdictions in which the Company may sell its products;
  • risks of litigation, including product liability claims or recalls, sales and marketing practices, intellectual property disputes, anti-trust claims and government investigations generally;
  • changes or disruptions in financial markets;
  • increased infrastructure, marketing and/or operating costs;
  • limits of insurance coverage and uninsurable risk;
  • failure to comply with laws and regulations or other regulatory requirements;
  • the inability of the Company to retain its key management employees and shortages of skilled personnel and contractors;
  • influence of third party stakeholders;
  • failures or deficiencies in the Company’s system of internal controls;
  • conflicts of interest;
  • credit and/or liquidity risks;
  • general regulatory environment in which the Company operates, including the areas of taxation, environmental protection, consumer safety and health regulation;
  • political instability, hostilities, insurrection or acts of war or terrorism;
  • adverse changes in government legislation and regulation;
  • general business, economic, competitive, political, regulatory and social uncertainties; and
  • the risks involved in the generic pharmaceutical business generally.

The forward-looking statements included on this website are made only as of the date they are made and the Company undertakes no obligation to update any forward-looking statements to reflect subsequent events or circumstances. There can be no assurance that the projected results can be realized or that actual results will not be materially higher or lower than those projected.